Clinical drug development for childhood cancers

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 2, 2009, Pages 127-129

  Balis, F M ^a   Fox, E ^a   Widemann, B C ^a   Adamson, P C ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CHILDHOOD CANCER; CLINICAL FEATURE; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; MAXIMUM TOLERATED DOSE; MORTALITY; PATHOGENESIS; PHARMACODYNAMICS; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; SIGNAL TRANSDUCTION; TREATMENT PLANNING;

AGE FACTORS; ANTINEOPLASTIC AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASMS; PHARMACOLOGY, CLINICAL; TECHNOLOGY, PHARMACEUTICAL;

EID: 58449102663     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.237     Document Type: Short Survey

References (4)

1. National Cancer Institute. SEER Cancer Statistics Review, 1975-2005. 〈http://seer.cancer.gov/report-to-nation/〉 (2008).
2. Crist, W.M. et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J. Clin. Oncol. 19, 3091-3102 (2001).
3. Lee, D.P., Skolnik, J.M. & Adamson, P.C. Pediatric phase I trials in oncology: an analysis of study conduct efficiency. J. Clin. Oncol. 23, 8431-8341 (2005).
4. Pappo, A.S. et al. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. J. Clin. Oncol. 25, 362-369 (2007).